For the all semaglutide OW cohort, eligible adults (aged 18 years) with 1 diagnosis on a confirmatory medical claim for T2D (any time prior to and including the index date) who initiated semaglutide OW with 2 filled prescription claims were identified, with the first claim during the selection window of January 1, 2018 to February 28, 2022, and the second claim during the follow-up period (1-year period after the index date)
For the semaglutide 2.4-mg-containing groups, semaglutide was initiated at 0.25 mg once weekly for the first 4 weeks, with the dose increased to 0.5 mg from weeks 5 to 8, to 1.0 mg from weeks 9 to 12, to 1.7 mg from weeks 13 to 16 and to 2.4 mg from weeks 17 to 71
This allows tissue recovery and reduces the buildup of irritation
No, it shouldnt
Persistent or severe constipation particularly if accompanied by abdominal pain, distension, nausea, vomiting, rectal bleeding, unintentional weight loss, or anaemiawarrants urgent medical review